Dietary Supplement
Conjugated Linoleic Acid (CLA)
Conjugated Linoleic Acid (CLA) is a dietary supplement with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DIETARY SUPPLEMENT
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph not_applicable
2
50%
Ph early_phase_1
1
25%
Ph phase_1
1
25%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
N/ANon-phased studies
2(50.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(4)
Detailed Status
Completed4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Early Phase 11 (25.0%)
Phase 11 (25.0%)
N/A2 (50.0%)
Trials by Status
completed4100%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus
NCT00607945
completedearly_phase_1
Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
NCT00908791
completednot_applicable
Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)
NCT01121471
completednot_applicable
The Health Benefits of Conjugated Linoleic Acid (CLA) for Asthma & Allergy
NCT00876356
Clinical Trials (4)
Showing 4 of 4 trials
NCT00607945Phase 1
Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus
NCT00908791Early Phase 1
Proof of Principle Trial to Determine if Nutritional Supplement Conjugated Linoleic Acid (CLA) Can Modulate the Lipogenic Pathway in Breast Cancer Tissue
NCT01121471Not Applicable
Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)
NCT00876356Not Applicable
The Health Benefits of Conjugated Linoleic Acid (CLA) for Asthma & Allergy
All 4 trials loaded
Drug Details
- Intervention Type
- DIETARY SUPPLEMENT
- Total Trials
- 4